Live Radio
The Food And Drug Administration in White Oak, Maryland. An FDA panel met Tuesday to review data from Pfizer's COVID-19 vaccine for children ages 5 - 11. Sarah Silbiger/Getty Images hide caption
The Food And Drug Administration in White Oak, Maryland. An FDA panel met Tuesday to review data from Pfizer's COVID-19 vaccine for children ages 5 - 11.
Sarah Silbiger/Getty ImagesThe CDC has now released booster guidance for all three vaccines available in the U.S. — making tens of millions of people eligible for another shot. And on Tuesday, an FDA panel met to review data from Pfizer on their vaccine for children ages 5 - 11.
NPR's Alison Aubrey explains what those data say about the vaccine — and how it might be rolled out.
Pediatrician Dr. Reah Boyd tells NPR how she's talking to parents about vaccinating their young children.
Additional reporting in this episode from NPR's Pien Huang, Rob Stein, and Selena Simmons-Duffin.
Email us at
This episode was produced by Brent Baughman, Mano Sundaresan, and Kat Lonsdorf. It was edited by Sarah Handel, Courtney Dorning, Joe Neel, and Fatma Tanis. Engineering help from Neal Rauch. Our executive producer is Cara Tallo.
